Home › Alzheimer's Disease › Texas › Beaumont
Alzheimer's Disease clinical trials in Beaumont, TX
6 studies for Alzheimer's Disease are looking for participants at sites in and around Beaumont (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
RecruitingPhase 2
- Gadolin Research, Beaumont
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RecruitingPhase 3
- Gadolin Research, LLC, Beaumont
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
RecruitingPhase 2
- Gadolin Research ( Site 1032), Beaumont
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
RecruitingPhase 3
- Gadolin Research, Beaumont
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
RecruitingPhase 3
- Gadolin Research, Beaumont
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
RecruitingObservational studyHealthy volunteers welcome
- Gadolin Research LLC, Beaumont
About Alzheimer's Disease
Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills. It's the most common cause of dementia among older adults.
More about Alzheimer's Disease on MedlinePlus
Alzheimer's Disease trials in other cities
- Boston, MA26 studies
- Orlando, FL25 studies
- St. Louis, MO22 studies
- New York City, NY21 studies
- Miami, FL20 studies
- Tampa, FL17 studies
- Atlanta, GA16 studies
- Philadelphia, PA15 studies
- The Villages, FL15 studies
- Phoenix, AZ15 studies
- Los Angeles, CA14 studies
- Indianapolis, IN14 studies
Other studies in Beaumont
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.